Werewolf TherapeuticsHOWL
HOWL
About: Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Employees: 45
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
107% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 14
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
4% more funds holding
Funds holding: 69 [Q3] → 72 (+3) [Q4]
8% more call options, than puts
Call options by funds: $43K | Put options by funds: $40K
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
10.51% less ownership
Funds ownership: 73.73% [Q3] → 63.22% (-10.51%) [Q4]
39% less capital invested
Capital invested by funds: $68.3M [Q3] → $41.7M (-$26.6M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
217%
upside
Avg. target
$9.50
654%
upside
High target
$15
1,090%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andres Maldonado 19% 1-year accuracy 9 / 47 met price target | 1,090%upside $15 | Buy Reiterated | 12 Mar 2025 |
JMP Securities Reni Benjamin 14% 1-year accuracy 5 / 37 met price target | 217%upside $4 | Market Outperform Maintained | 14 Jan 2025 |
Financial journalist opinion
Based on 3 articles about HOWL published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively –
Neutral
GlobeNewsWire
1 week ago
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J.
Neutral
GlobeNewsWire
2 weeks ago
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors.
Neutral
GlobeNewsWire
1 month ago
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways –
Neutral
GlobeNewsWire
3 months ago
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 12:55 pm ET on Thursday, December 5, 2024, at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, taking place December 3-5 in Miami, Florida.
Neutral
GlobeNewsWire
4 months ago
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
Neutral
GlobeNewsWire
5 months ago
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.
Negative
Zacks Investment Research
7 months ago
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago.
Neutral
GlobeNewsWire
7 months ago
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting –
Positive
Seeking Alpha
8 months ago
Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Werewolf Therapeutics, Inc. is an early-stage biotech focusing on cytokine therapy for cancer treatment. The Pipeline update includes positive results for WTX-124 in clinical trials and promising data for WTX-330. Financially, the company has a decent cash position for now, but may need to address cash burn rate in the near future.
Charts implemented using Lightweight Charts™